Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thioguanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | HPGD | P15428 | 3/20 | 0.79 |
| ▸ | TP53 | P04637 | 2/20 | 0.79 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.79 |
| ▸ | HBB | P68871 | 2/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.79 |
| ▸ | XDH | P47989 | 2/20 | 0.79 |
| ▸ | USP2 | O75604 | 1/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.79 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.79 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.37 |
| ▸ | PNP | P00491 | 1/20 | 0.37 |
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.34 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioguanine SCHEMBL31327802 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HPGDTP53PTGS1HBB | |
| Thioguanine SCHEMBL3702 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HPGDTP53PTGS1HBB | |
| Thioguanine SCHEMBL28134237 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HPGDTP53PTGS1HBB | |
| Thioguanine SCHEMBL28189107 | 0.87 | ALDH1A1 (0.96) | ALDH1A1HPGDTP53PTGS1HBB | |
| Thioguanine SCHEMBL28105522 | 0.87 | ALDH1A1 (0.96) | ALDH1A1HPGDTP53PTGS1HBB | |
| Thioguanine SCHEMBL27871418 | 0.87 | ALDH1A1 (0.96) | ALDH1A1HPGDTP53PTGS1HBB | |
| Thioguanine SCHEMBL27820845 | 0.83 | ALDH1A1 (0.87) | ALDH1A1HPGDTP53PTGS1HBB | |
| Thioguanine SCHEMBL28286968 | 0.81 | ALDH1A1 (0.84) | ALDH1A1HPGDTP53PTGS1HBB | |
| Thioguanine SCHEMBL1829348 | 0.79 | ALDH1A1 (0.49) | ALDH1A1HPGDTP53PTGS1HBB | |
| Thioguanine SCHEMBL27688865 | 0.79 | ALDH1A1 (0.79) | ALDH1A1HPGDTP53PTGS1HBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 830 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4319736-A1 | MALIGNANT NEOPLASIS TREATMENT USING PD-1 ANTIBODY COMBINATION | Joint Stock Company "Biocad" (RU) | 2024-02-14 | — | — | EP | disclosed |
| US-11840567-B2 | Bispecific antibodies with specific binding to CD47 and PD-L1 | JOINT STOCK COMPANY "BIOCAD" (RU) | 2023-12-12 | — | — | US | disclosed |
| EP-3875486-A1 | MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO CD20 | Joint Stock Company "Biocad" (RU) | 2021-09-08 | — | — | EP | disclosed |
| US-20200270345-A1 | Antibodies specific to CD47 and PD-L1 | JOINT STOCK COMPANY "BIOCAD" (RU) | 2020-08-27 | — | — | US | disclosed |
| EP-3693390-A1 | ANTIBODIES SPECIFIC TO CD47 AND PD-L1 | Joint Stock Company "Biocad" (RU) | 2020-08-12 | — | — | EP | disclosed |
| CN-110536703-A | Use Anti-AXL antibodies-drug conjugate combination treatment | ADC THERAPEUTICS SA | 2019-12-03 | — | — | CN | disclosed |
| CN-110526912-A | Heteroaryl compound for kinase inhibition | ARIAD PHARMA INC | 2019-12-03 | — | — | CN | disclosed |
| CN-110511279-A | Oncostatin M receptor antigen binding proteins | KINIKSA PHARMACEUTICALS LTD | 2019-11-29 | — | — | CN | disclosed |
| CN-110520118-A | PRODRUGS OF GLUTAMINE ANALOGS | UNIV JOHNS HOPKINS | 2019-11-29 | — | — | CN | disclosed |
| CN-110520533-A | The VEGFR-2 CAR immunocyte for the treatment of cancer | HELIX BIOPHARMA CORP | 2019-11-29 | — | — | CN | disclosed |
| CN-101198623-A | Methods and compositions for modulating and detecting WISP activity | GENENTECH INC (US) | 2008-06-11 | — | — | CN | disclosed |
| CN-101193910-A | HGF beta chain variants | GENENTECH INC (US) | 2008-06-04 | — | — | CN | disclosed |
| CN-101184507-A | Treatment of inflammatory bowel disease (ibd) | GENENTECH INC (US) | 2008-05-21 | — | — | CN | disclosed |
| CN-101180072-A | Methods of using death receptor agonists and egfr inhibitors | GENENTECH INC (US) | 2008-05-14 | — | — | CN | disclosed |
| CN-101166764-A | Treatment of bone disorders | GENENTECH INC (US) | 2008-04-23 | — | — | CN | disclosed |
| CN-101151278-A | CD20 antibody variants and uses thereof | GENENTECH INC (US) | 2008-03-26 | — | — | CN | disclosed |
| CN-101115836-A | Inhibiting her2 shedding with matrix metalloprotease antagonists | GENENTECH INC (US) | 2008-01-30 | — | — | CN | disclosed |
| CN-101102793-A | Treatment method | GENENTECH INC (US) | 2008-01-09 | — | — | CN | disclosed |
| CN-101039957-A | Synthetic chemokine receptor ligands and methods of use thereof | INTERMUNE INC (US) | 2007-09-19 | — | — | CN | disclosed |
| CN-1993142-A | Method for treating lupus | GENENTECH INC (US) | 2007-07-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270345-A1 | Antibodies specific to CD47 and PD-L1 | CD47, CD274, PDCD1LG2 | ALDH1A1 3479/4885HPGD 4345/4885TP53 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.